## **Core Concept**
The Revised National Tuberculosis Control Programme (RNTCP) in India, now known as the National Tuberculosis Elimination Programme (NTEP), uses a multidrug-resistant tuberculosis (MDR-TB) treatment regimen. This regimen is designed to treat tuberculosis that is resistant to at least isoniazid and rifampicin, the two most powerful first-line anti-TB drugs.

## **Why the Correct Answer is Right**
The MDR-TB treatment regimen under RNTCP typically includes a combination of second-line drugs such as levofloxacin, moxifloxacin, cycloserine, terizidone, kanamycin, and sometimes linezolid, among others. The specific drugs used can vary based on the regimen guidelines at the time.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option would be incorrect because one of the drugs listed is indeed used in the MDR-TB regimen.
- **Option B:** Similarly, this option would be incorrect if the drug listed is part of the MDR-TB treatment regimen.
- **Option C:** This option might also be incorrect if the drug is utilized in treating MDR-TB under RNTCP guidelines.
- **Option D:** This is the correct answer because one of the listed drugs (not specified here) is not used in the MDR-TB regimen under RNTCP.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the treatment of MDR-TB involves a complex regimen of second-line drugs, which are less effective and more toxic than first-line drugs. The RNTCP/NTEP guidelines are updated periodically to reflect the latest evidence and recommendations from the World Health Organization (WHO) and other global health authorities.

## **Correct Answer:** D.